Literature DB >> 454469

2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.

J R Bertino, W L Sawicki, B A Moroson, A R Cashmore, E F Elslager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 454469     DOI： 10.1016/0006-2952(79)90655-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  17 in total

1.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.

Authors:  P Rogers; C J Allegra; R F Murphy; J C Drake; H Masur; D G Poplack; B A Chabner; J E Parrillo; H C Lane; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

3.  Trimetrexate: a new antifol entering clinical trials.

Authors:  P J O'Dwyer; D D Shoemaker; J Plowman; J Cradock; A Grillo-Lopez; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

4.  Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate.

Authors:  V I Polshakov; B Birdsall; T A Frenkiel; A R Gargaro; J Feeney
Journal:  Protein Sci       Date:  1999-03       Impact factor: 6.725

5.  A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).

Authors:  Y Takemura; T Ohnuma; H Miyachi; S Sekiguchi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712.

Authors:  W H Harvey; T R Fleming; P J Goodman; J H Harvey; S E Rivkin; J S MacDonald
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

7.  Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study.

Authors:  T R Fleming; T D Brown; S W Ross; J S Macdonald
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.

Authors:  L B Grochow; D A Noe; D S Ettinger; R C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

10.  Cell cycle effects of trimetrexate (CI-898).

Authors:  K E Hook; J M Nelson; B J Roberts; D P Griswold; W R Leopold
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.